Cellectis S.A. NASDAQ:CLLS

Founder-led company

Cellectis S.A. stock price today

$2.99
+1.58
+112.06%
Financial Health
0
1
2
3
4
5
6
7
8
9

Cellectis S.A. stock price monthly change

-32.54%
month

Cellectis S.A. stock price quarterly change

-32.54%
quarter

Cellectis S.A. stock price yearly change

-59.37%
year

Cellectis S.A. key metrics

Market Cap
109.55M
Enterprise value
67.80M
P/E
-1.01
EV/Sales
3.07
EV/EBITDA
-0.87
Price/Sales
4.08
Price/Book
0.65
PEG ratio
1.97
EPS
-1.02
Revenue
5.14M
EBITDA
-84.11M
Income
-65.34M
Revenue Q/Q
3157.55%
Revenue Y/Y
-70.98%
Profit margin
-497.34%
Oper. margin
-636.4%
Gross margin
44.94%
EBIT margin
-636.4%
EBITDA margin
-1635.17%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Cellectis S.A. stock price history

Cellectis S.A. stock forecast

Cellectis S.A. financial statements

Cellectis S.A. (NASDAQ:CLLS): Profit margin
Jun 2023 178K -10.64M -5982.02%
Sep 2023 155K -17.48M -11278.71%
Dec 2023 283K -42.86M -15145.58%
Mar 2024 4.52M 5.64M 124.62%
Cellectis S.A. (NASDAQ:CLLS): Analyst Estimates
Sep 2025 6.59M -28.86M -437.83%
Dec 2025 197.25K -20.94M -10620.42%
Dec 2025 10.61M -28.86M -272.02%
Mar 2026 3.07M -33.79M -1097.46%
  • Analysts Price target

  • Financials & Ratios estimates

Cellectis S.A. (NASDAQ:CLLS): Earnings per share (EPS)
2022-11-03 -0.46 -0.63
2023-03-08 -0.49029 -0.59
Cellectis S.A. (NASDAQ:CLLS): Debt to assets
Jun 2023 227674000 131.11M 57.59%
Sep 2023 209700000 133.57M 63.7%
Dec 2023 334270000 249.57M 74.66%
Mar 2024 354459000 263.89M 74.45%
Cellectis S.A. (NASDAQ:CLLS): Cash Flow
Jun 2023 -19.04M -1.78M 19.81M
Sep 2023 -17.09M -300K 1.68M
Dec 2023 39.61M -13.65M 41.68M
Mar 2024 -23.54M -2.05M 12.12M

Cellectis S.A. alternative data

Company's Focus On Multiple Cancers Including

Cellectis S.A. (NASDAQ:CLLS): Google Trends - Company's Focus On Multiple Cancers Including
21 May 2023 121734
28 May 2023 131831
4 Jun 2023 1311532
11 Jun 2023 131632
18 Jun 2023 141632
25 Jun 2023 111632
2 Jul 2023 111635
9 Jul 2023 101631
16 Jul 2023 101531
23 Jul 2023 101634
30 Jul 2023 121734
6 Aug 2023 121634
13 Aug 2023 101632
20 Aug 2023 92631
27 Aug 2023 101632
3 Sep 2023 101630
10 Sep 2023 101630
17 Sep 2023 112630
24 Sep 2023 101635
1 Oct 2023 91632

Gene editing

Cellectis S.A. (NASDAQ:CLLS): Google Trends - Gene editing
21 May 2023 11
28 May 2023 12
4 Jun 2023 11
11 Jun 2023 12
18 Jun 2023 14
25 Jun 2023 15
2 Jul 2023 19
9 Jul 2023 18
16 Jul 2023 16
23 Jul 2023 27
30 Jul 2023 22
6 Aug 2023 16
13 Aug 2023 19
20 Aug 2023 16
27 Aug 2023 19
3 Sep 2023 20
10 Sep 2023 21
17 Sep 2023 23
24 Sep 2023 25
1 Oct 2023 21

Gene Editing Companies

Cellectis S.A. (NASDAQ:CLLS): Google Trends - Gene Editing Companies
21 May 2023 24141016
28 May 2023 12031211
4 Jun 2023 1805154
11 Jun 2023 2102127
18 Jun 2023 180597
25 Jun 2023 1905117
2 Jul 2023 1616217
9 Jul 2023 1422104
16 Jul 2023 1403119
23 Jul 2023 37081511
30 Jul 2023 25171511
6 Aug 2023 2706167
13 Aug 2023 2174104
20 Aug 2023 1914137
27 Aug 2023 1708138
3 Sep 2023 1927195
10 Sep 2023 2215206
17 Sep 2023 37092911
24 Sep 2023 470113129
1 Oct 2023 421113020

Types of gene editing

Cellectis S.A. (NASDAQ:CLLS): Google Trends - Types of gene editing
5 Mar 2023 11200
12 Mar 2023 12180
19 Mar 2023 9191
26 Mar 2023 9210
2 Apr 2023 9221
9 Apr 2023 21310
16 Apr 2023 16241
23 Apr 2023 13231
30 Apr 2023 11210
7 May 2023 10610
14 May 2023 13371
21 May 2023 9301
28 May 2023 10291
4 Jun 2023 10241
11 Jun 2023 10290
18 Jun 2023 10291
25 Jun 2023 11281
2 Jul 2023 9351
9 Jul 2023 19391
16 Jul 2023 100340

Numbers represent search interest relative to the highest point on the chart for the given region and time.

A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.

Cellectis S.A. (NASDAQ:CLLS): Job openings
Aug 2023 4
Sep 2023 2
Oct 2023 2
Nov 2023 1
Dec 2023 4
Jan 2024 4
Feb 2024 4
Apr 2024 4
May 2024 15
Jun 2024 30
Jul 2024 27
Dec 2024 9
Cellectis S.A. (NASDAQ:CLLS): Employee count
Aug 2023 231
Sep 2023 231
Oct 2023 231
Nov 2023 231
Dec 2023 231
Jan 2024 231
Feb 2024 231
Mar 2024 231
Apr 2024 231
May 2024 231
Jun 2024 216
Jul 2024 216

Cellectis S.A. other data

16.13% -3.06%
of CLLS is owned by hedge funds
7.34M -1.38M
shares is hold by hedge funds
Patent
Application
Filling date: 30 Mar 2018 Issue date: 3 Jun 2021
Application
Filling date: 30 Mar 2018 Issue date: 8 Apr 2021
Application
Filling date: 13 Nov 2020 Issue date: 4 Mar 2021
Insider Compensation
Dr. Andre Choulika Ph.D. (1965) Co-Founder, Chief Executive Officer & Director $1,150,000
Dr. David J. D. Sourdive Ph.D. (1967) Co-Founder, Executive Vice President of CMC and Manufacturing & Director
$476,630
Thursday, 12 December 2024
seekingalpha.com
Tuesday, 10 December 2024
globenewswire.com
Tuesday, 5 November 2024
globenewswire.com
seekingalpha.com
Monday, 4 November 2024
globenewswire.com
Wednesday, 30 October 2024
globenewswire.com
Tuesday, 22 October 2024
globenewswire.com
Tuesday, 3 September 2024
globenewswire.com
Monday, 26 August 2024
globenewswire.com
Wednesday, 7 August 2024
globenewswire.com
Tuesday, 6 August 2024
globenewswire.com
Thursday, 1 August 2024
globenewswire.com
Thursday, 25 July 2024
globenewswire.com
Wednesday, 10 July 2024
zacks.com
Friday, 28 June 2024
globenewswire.com
Thursday, 20 June 2024
globenewswire.com
Tuesday, 18 June 2024
zacks.com
zacks.com
Wednesday, 12 June 2024
globenewswire.com
Tuesday, 4 June 2024
globenewswire.com
Thursday, 30 May 2024
seekingalpha.com
seekingalpha.com
Wednesday, 29 May 2024
globenewswire.com
Tuesday, 28 May 2024
globenewswire.com
Monday, 27 May 2024
globenewswire.com
Monday, 6 May 2024
globenewswire.com
Thursday, 2 May 2024
globenewswire.com
Monday, 29 April 2024
globenewswire.com
Monday, 22 April 2024
globenewswire.com
Wednesday, 10 April 2024
globenewswire.com
  • What's the price of Cellectis S.A. stock today?

    One share of Cellectis S.A. stock can currently be purchased for approximately $2.99.

  • When is Cellectis S.A.'s next earnings date?

    Unfortunately, Cellectis S.A.'s (CLLS) next earnings date is currently unknown.

  • Does Cellectis S.A. pay dividends?

    No, Cellectis S.A. does not pay dividends.

  • How much money does Cellectis S.A. make?

    Cellectis S.A. has a market capitalization of 109.55M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 96.06% to 755K US dollars. Cellectis S.A. made a loss 101.06M US dollars in net income (profit) last year or -$0.59 on an earnings per share basis.

  • What is Cellectis S.A.'s stock symbol?

    Cellectis S.A. is traded on the NASDAQ under the ticker symbol "CLLS".

  • What is Cellectis S.A.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Cellectis S.A.?

    Shares of Cellectis S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Cellectis S.A.'s key executives?

    Cellectis S.A.'s management team includes the following people:

    • Dr. Andre Choulika Ph.D. Co-Founder, Chief Executive Officer & Director(age: 60, pay: $1,150,000)
    • Dr. David J. D. Sourdive Ph.D. Co-Founder, Executive Vice President of CMC and Manufacturing & Director(age: 58, pay: $476,630)
  • Is Cellectis S.A. founder-led company?

    Yes, Cellectis S.A. is a company led by its founders Dr. Andre Choulika Ph.D. and Dr. David J. D. Sourdive Ph.D..

  • How many employees does Cellectis S.A. have?

    As Jul 2024, Cellectis S.A. employs 216 workers, which is 6% less then previous quarter.

  • When Cellectis S.A. went public?

    Cellectis S.A. is publicly traded company for more then 10 years since IPO on 24 Mar 2015.

  • What is Cellectis S.A.'s official website?

    The official website for Cellectis S.A. is cellectis.com.

  • How can i contact Cellectis S.A.?

    Cellectis S.A. can be reached via phone at +33 1 81 69 16 00.

Cellectis S.A. company profile:

Cellectis S.A.

cellectis.com
Exchange:

NASDAQ

Full time employees:

216

Industry:

Biotechnology

Sector:

Healthcare

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

8, rue de la Croix Jarry
Paris, 75013

CIK: 0001627281
ISIN: US15117K1034
CUSIP: 15117K103